sulfasalazine and Aura
sulfasalazine has been researched along with Aura in 6 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a case of seizures with acute encephalopathy in a female patient under sulfasalazine treatment for polyarthritis." | 3.71 | [Sulfasalazine neurotoxicity]. ( Chadenat, ML; Dechy, H; Dorra, M; Dupont, C; Morelon, S; Raffin-Sanson, ML; Rouveix, E, 2001) |
| "Sulfasalazine (SAS) is an US Food and Drug Administration (FDA)-approved drug for the treatment of Crohn disease that has been shown to inhibit the cystine/glutamate antiporter system xc- (SXC) and decrease tumor-associated seizures." | 1.51 | Sulfasalazine decreases mouse cortical hyperexcitability. ( Alcoreza, O; Bouslog, A; Campbell, SL; Savoia, A; Sontheimer, H; Tewari, BP, 2019) |
Research
Studies (6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Alcoreza, O | 2 |
| Jagarlamudi, S | 1 |
| Savoia, A | 2 |
| Campbell, SL | 3 |
| Sontheimer, H | 4 |
| Pietropaoli, S | 1 |
| Leonetti, A | 1 |
| Cervetto, C | 1 |
| Venturini, A | 1 |
| Mastrantonio, R | 1 |
| Baroli, G | 1 |
| Persichini, T | 1 |
| Colasanti, M | 1 |
| Maura, G | 1 |
| Marcoli, M | 1 |
| Mariottini, P | 1 |
| Cervelli, M | 1 |
| Tewari, BP | 1 |
| Bouslog, A | 1 |
| Buckingham, SC | 1 |
| Haas, BR | 1 |
| Montana, V | 1 |
| Robel, S | 1 |
| Ogunrinu, T | 1 |
| Bridges, RJ | 1 |
| Chadenat, ML | 1 |
| Morelon, S | 1 |
| Dupont, C | 1 |
| Dechy, H | 1 |
| Raffin-Sanson, ML | 1 |
| Dorra, M | 1 |
| Rouveix, E | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial Combining Sulfasalazine and Gamma Knife Radiosurgery for Recurrent Glioblastoma[NCT04205357] | Phase 1 | 24 participants (Actual) | Interventional | 2020-03-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Other Studies
6 other studies available for sulfasalazine and Aura
| Article | Year |
|---|---|
Sulfasalazine decreases astrogliosis-mediated seizure burden.
Topics: Animals; Antiporters; Electroencephalography; Epilepsy; Gliosis; Glutamic Acid; Humans; Mice; Seizur | 2022 |
Glutamate Excitotoxicity Linked to Spermine Oxidase Overexpression.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Amino Acid Transport System y+; Animals; Behavior, Animal; Brain; Deoxy | 2018 |
Sulfasalazine decreases mouse cortical hyperexcitability.
Topics: Animals; Anticonvulsants; Brain; Disease Models, Animal; Epilepsy; Excitatory Postsynaptic Potential | 2019 |
Glutamate release by primary brain tumors induces epileptic activity.
Topics: Amino Acid Transport System y+; Analysis of Variance; Animals; Brain Neoplasms; Cell Transplantation | 2011 |
Sulfasalazine for brain cancer fits.
Topics: Amino Acid Transport System y+; Animals; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Ep | 2012 |
[Sulfasalazine neurotoxicity].
Topics: Acute Disease; Adult; Antirheumatic Agents; Arthritis; Encephalitis; Epilepsy; Female; Humans; Sulfa | 2001 |